Overview
Secukinumab is a monoclonal antibody that specifically targets interleukin-17A (IL-17A), a cytokine implicated in the pathogenesis of several autoimmune diseases. Developed by Novartis, it has been approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. By neutralizing IL-17A, secukinumab reduces inflammation and slows disease progression, offering significant clinical benefits to patients.
Physical and Chemical Properties
Secukinumab is a human IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is formulated as a clear to opalescent, colorless to slightly yellow solution, typically administered via subcutaneous injection. The antibody is highly soluble in water and stable under recommended storage conditions (2-8°C). Its specificity for IL-17A ensures minimal off-target effects, making it a precise therapeutic agent.
Main Applications
Secukinumab is primarily used to treat autoimmune conditions characterized by excessive IL-17A activity. It is highly effective in managing moderate to severe plaque psoriasis, reducing skin lesions and improving quality of life. Additionally, it is prescribed for psoriatic arthritis and ankylosing spondylitis, where it alleviates joint pain and stiffness. Ongoing research explores its potential in other IL-17A-mediated diseases.
Safety and Storage
Patients using secukinumab may be at increased risk of infections due to its immunosuppressive effects. Common side effects include upper respiratory infections and injection-site reactions. Proper storage at 2-8°C is critical to maintain efficacy, and exposure to light should be minimized. Healthcare providers should monitor patients for hypersensitivity reactions and advise against live vaccinations during treatment.
B2B Procurement Guide
When procuring secukinumab, B2B buyers should prioritize suppliers with robust cold chain logistics to ensure product integrity. Verify regulatory approvals, such as FDA or EMA certifications, to guarantee compliance. Bulk purchases may offer cost advantages, but storage capacity must align with demand. Partnering with reputable pharmaceutical distributors ensures reliable supply and post-purchase support.